Genetic haplotypes in <i>VWA8, OSBPL6,</i> and <i>ADAMTS9-AS2</i> are associated with immune-related adverse effects in ICI-treated patients with cancer.

J Immunother Cancer · 2025 · PMC12570911 · PMID 41151836

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

CXCL16 also showed a trend of greater downregulation in the risk group (median log2 FC –0.15 in risk vs –0.07 in non-risk), although the difference was not statistically significant (p=0.40).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Genetic haplotypes in &lt;i&gt;VWA8, OSBPL6,&lt;/i&gt; and &lt;i&gt;ADAMTS9-AS2&lt;/i&gt; are associated with immune-related adverse effects in ICI-treated patients with cancer.

The sentences

Genetic haplotypes in <i>VWA8, OSBPL6,</i> and <i>ADAMTS9-AS2</i> are associated with immune-related adverse effects in ICI-treated patients with cancer.